Aspira Women’s Health Announces Upcoming Earnings Results
Aspira Women’s Health Inc. (Nasdaq: AWH), a pioneering bio-analytical company specializing in women’s health diagnostics, has exciting news to share with stakeholders. The company is preparing to disclose its financial results for the third quarter, marking the end of September 2024. This important announcement is set to take place on an upcoming Thursday.
Details of the Financial Disclosure
Management will host a conference call at 8:30 am ET on the designated day to discuss the financial outcomes and provide insightful corporate updates. Aspira’s commitment to transparency ensures shareholders and interested parties are informed about the company’s progress and future direction.
Conference Call Information
For those wishing to join the conversation, they can access the call via toll-free lines or international dialing options. Details are as follows:
- Date: Upcoming Thursday
- Time: 8:30 am ET
- Toll-Free Number: 877-545-0320
- International Number: 973-528-0002
- Access Code: 436613
Webcast Availability
A live audio webcast will also be available for those who cannot join via the call. Following the event, a replay will be accessible to allow for convenient access to the information presented.
About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. is at the forefront of developing innovative, non-invasive tests powered by artificial intelligence aimed at diagnosing gynecologic diseases effectively. Their unique tests, OvaWatch and Ova1Plus, are marketed under the OvaSuite brand and are instrumental in assessing ovarian cancer risk in women diagnosed with an adnexal mass.
Innovative Diagnostic Solutions
OvaWatch boasts an impressive negative predictive value of 99%, providing essential insights for clinicians when the initial tests indicate a mass might be benign or uncertain. Furthermore, Ova1Plus employs a reflexive assessment process amalgamating two FDA-cleared tests to evaluate ovarian malignancy risk for women slated for surgery.
Expansion of Test Offerings
Aspira’s dedication to improving women’s health is evident in their expanding pipeline of tests focused on ovarian cancer and endometriosis. The organization is leveraging the combination of microRNA and protein biomarkers with patient data, aiming to enhance the sensitivity and specificity of existing tests significantly.
Future Directions and Innovations
In addition to ovarian cancer diagnostics, the company has identified a critical need for non-invasive diagnostic tests for endometriosis, a condition affecting countless women globally. Aspira is pioneering the development of a novel non-invasive test tailored specifically to identify endometriomas, which represent a common and severe form of endometriosis.
Through dedicated research and innovation, Aspira aims to standardize ovarian cancer screenings and effectively address the multifaceted challenges associated with diagnosing gynecological conditions. This commitment positions Aspira Women’s Health as a leader in advancing women’s healthcare diagnostics.
Contact Information
For inquiries, reach out to:
Jamie Sullivan
Director of Corporate Communications
Aspira Women’s Health
Email: Investors@aspirawh.com
Frequently Asked Questions
What is the significance of the upcoming earnings report?
The earnings report provides critical insights into Aspira Women’s Health’s financial performance, informing investors and stakeholders about the company's progress and future plans.
How can I participate in the earnings call?
Interested parties can join the earnings call via toll-free or international numbers. Specific dial-in details are provided in the announcement.
What innovative products does Aspira offer?
Aspira offers OvaWatch and Ova1Plus under the OvaSuite brand, providing critical diagnostic tools for ovarian cancer risk assessment.
What are Aspira's future diagnostic plans?
Aspira is focused on expanding their test portfolio, addressing urgent needs in both ovarian cancer and endometriosis diagnostics.
Who can I contact for investor relations?
Jamie Sullivan is available for any inquiries regarding investor relations at Aspira Women’s Health. You can contact her at Investors@aspirawh.com.
